Illumina, Inc.

FTC Orders Illumina to Divest Cancer Detection Test Maker GRAIL to Protect Competition in Life-Saving Technology Market

Retrieved on: 
Monday, April 17, 2023
Commissioner, Review, DNA, Commission, Opinion, NGS, Cancer, Blog, Social media, Federal Trade Commission, Sale, Complaint, Appellate court, GRAIL, Acquisition, Patient, In re Opinions and Orders of This Court Containing Novel or Significant Interpretations of Law (2016), FTC, Efficiency, Administrative law, News, Federal Trade Commission v. Meta Platforms, Inc., Synovial joint, Illumina, Inc., Medical imaging, Illumina

GRAIL makes non-invasive, early detection liquid biopsy tests that can screen for multiple types of cancer in asymptomatic patients at very early stages using DNA sequencing.

Key Points: 
  • GRAIL makes non-invasive, early detection liquid biopsy tests that can screen for multiple types of cancer in asymptomatic patients at very early stages using DNA sequencing.
  • These tests could be used to detect multiple types of cancer, most of which are not screened for at all today.
  • - Illumina has an enormous financial incentive to ensure that GRAIL wins the innovation race in the U.S. MCED market.
  • Illumina stands to earn substantially more profit on the sale of GRAIL tests than it does by supporting rival test developers.

Global Short-read Sequencing Market 2023 - 2030: Rising Adoption of Short-read Sequencing for Personalized Medicine and Companion Diagnostics Drives Growth - ResearchAndMarkets.com

Retrieved on: 
Monday, April 17, 2023
Biotechnology, Genetics, Health, Amgen, Workflow, COVID-19, Infection, Research, Noninvasive prenatal testing, USD, Government, Patient, Application, Bangalore, Illumina, Inc., Indian Institute of Science, Viral, Sequencing, Vaccine, Fine chemical, Video game

The global short-read sequencing market size is expected to reach USD 18.67 billion by 2030, expanding at 18.46% CAGR from 2023 to 2030.

Key Points: 
  • The global short-read sequencing market size is expected to reach USD 18.67 billion by 2030, expanding at 18.46% CAGR from 2023 to 2030.
  • The rising demand for personalized medicine and companion diagnostics is anticipated to drive the demand for short-read technologies.
  • In addition, initiatives taken by key players to enhance their market presence are expected to boost revenue generation opportunities in the short-read sequencing industry.
  • Furthermore, a rise in the adoption of sequencing platforms for genomic research purposes is expected to have a positive impact on the overall market growth.

Next-generation Sequencing Services Market Research Report 2023: A $24.5 Billion Market by 2030 - Decline In Sequencing Prices Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Monday, April 10, 2023
Health, Genetics, Workflow, Laboratory, ARUP Laboratories, NGS, Clinical trial, Cancer, BGI, TSO, Research, RNA, USD, Human Genome Sequencing Center, Hospital, Patient, Physician, IVD, Growth, Oncology, Pneumonia, Genome, Illumina, Inc., Antibiotics, Vaccine, Pharmaceutical industry, Fine chemical, EU, Illumina

The "Next-generation Sequencing Services Market Size, Share & Trends Analysis Report By Service Type (Human Genome Sequencing, Gene Regulation Services), By Workflow, By End-use, And Segment Forecasts, 2023 - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Next-generation Sequencing Services Market Size, Share & Trends Analysis Report By Service Type (Human Genome Sequencing, Gene Regulation Services), By Workflow, By End-use, And Segment Forecasts, 2023 - 2030" report has been added to ResearchAndMarkets.com's offering.
  • The global next-generation sequencing services market size is expected to reach USD 24.5 billion by 2030 It is expected to expand at a CAGR of 22.56% from 2023 to 2030.
  • The development of next-generation sequencing (NGS) technologies has revolutionized gene sequencing in terms of reproducibility and cost savings.
  • This has resulted in the introduction of several advancements in NGS technology to promote its usage in clinical labs and hospitals.

Illumina and Henry Ford Health team up to study impact of comprehensive genomic testing for cardiovascular patients

Retrieved on: 
Monday, November 13, 2023
DNA, Partnership, Cardiovascular disease, Education, Genomics, Clinical Pharmacogenetics Implementation Consortium, Personalized medicine, Henry Ford Health, Food and Drug Administration, Genetic distance, Individualized medicine, Lisa, Pharmacist, Henry Ford, Patient, Standard of care, Risk, Physician, SAN, Illumina, Inc., Division, WGS, Diagnosis, Research, Health, American College, Death, Food, World Health Organization, Pharmaceutical industry, Illumina

SAN DIEGO, April 11, 2023 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, and Henry Ford Health, a not-for-profit health care organization in the Detroit metro area, today announced the launch of a partnership to assess the impact of comprehensive genomic testing in cardiovascular disease. The first study under this new partnership, CardioSeq, launches today and will include 1500 patients receiving care from the Division of Cardiovascular Medicine at Henry Ford.

Key Points: 
  • The first study under this new partnership, CardioSeq, launches today and will include 1500 patients receiving care from the Division of Cardiovascular Medicine at Henry Ford.
  • "This study is the first of several that will measure the impact of whole-genome sequencing in patients with cardiovascular disease," said Dr. David Lanfear , vice president of clinical and translational research at Henry Ford Health and the study's lead clinician.
  • Dr. Phil Febbo, chief medical officer of Illumina, added: "We are honored to partner with Henry Ford Health to assess the potential benefits of integrating genomic testing within specialized care centers in the health care system.
  • The CardioSeq study will use an accredited clinical test developed by Illumina that employs WGS to create a comprehensive cardiovascular genomic profile.

Illumina's revolutionary NovaSeq X exceeds 200th order milestone in first quarter 2023

Retrieved on: 
Tuesday, April 4, 2023
DNA, Broad Institute, Workflow, Research, Genomics, MIT, Harvard University, SAN, Illumina, Inc., Genome, Medical imaging, Illumina

SAN DIEGO, April 4, 2023 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced it has already exceeded more than 200 orders for its revolutionary NovaSeq X sequencing system in the first quarter of 2023. The orders represent a diverse customer base spanning research and clinical customer segments in nearly 30 countries, across five continents, all seeking to add NovaSeq X – our fastest, most powerful, most sustainable high-throughput sequencer available.

Key Points: 
  • SAN DIEGO, April 4, 2023 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced it has already exceeded more than 200 orders for its revolutionary NovaSeq X sequencing system in the first quarter of 2023.
  • "The NovaSeq X has enjoyed the strongest pre-launch demand we've ever seen for any instrument, and customer enthusiasm continues to grow," said Susan Tousi, chief commercial officer at Illumina.
  • "Customers are thrilled about NovaSeq X's ability to enable and accelerate new projects that require more samples, more multiomic analyses, and depth of sequencing.
  • In February, scientists at the Broad Institute of MIT and Harvard, the first recipient of a NovaSeq X, presented data confirming NovaSeq X Plus' performance meets or exceeds that of the NovaSeq 6000.

FTC Orders Illumina to Divest Cancer Detection Test Maker GRAIL to Protect Competition in Life-Saving Technology Market

Retrieved on: 
Tuesday, April 4, 2023
Commissioner, Review, DNA, Commission, Opinion, NGS, Cancer, Blog, Social media, Federal Trade Commission, Sale, Complaint, Appellate court, GRAIL, Acquisition, Patient, In re Opinions and Orders of This Court Containing Novel or Significant Interpretations of Law (2016), FTC, Efficiency, Administrative law, News, Federal Trade Commission v. Meta Platforms, Inc., Synovial joint, Illumina, Inc., Medical imaging, Illumina

GRAIL makes non-invasive, early detection liquid biopsy tests that can screen for multiple types of cancer in asymptomatic patients at very early stages using DNA sequencing.

Key Points: 
  • GRAIL makes non-invasive, early detection liquid biopsy tests that can screen for multiple types of cancer in asymptomatic patients at very early stages using DNA sequencing.
  • These tests could be used to detect multiple types of cancer, most of which are not screened for at all today.
  • - Illumina has an enormous financial incentive to ensure that GRAIL wins the innovation race in the U.S. MCED market.
  • Illumina stands to earn substantially more profit on the sale of GRAIL tests than it does by supporting rival test developers.

DNA Data Storage Alliance Announces Board Appointments

Retrieved on: 
Wednesday, March 29, 2023
Data Management, Biotechnology, Technology, Other Health, Health, General Health, Health Technology, Research, Nanotechnology, Genetics, Science, ECC, NVM Express, DNA, IBM, Oak Ridge, RAID, University, Roadrunner, Linear Tape-Open, DNA Data Bank of Japan, Quantum Corporation, SP, Propulsion Cryogenics & Advanced Development, HDD, Lawrence Livermore National Laboratory, San Diego State University, Western Digital, Cloud computing, Congress, Organization, WDC, Algorithm, HP Inc., Engineering, Physics, MSFT, Government, Digital, Mathematics, Summit, Chair, Illumina, Inc., ASIC, Computer data storage, Video game, LTO, Microsoft, Quantum

The DNA Data Storage Alliance, a SNIA Technology Affiliate, formed in 2020 by Illumina, Inc. (NASDAQ: ILMN), Microsoft (Nasdaq: MSFT), Twist Bioscience Corporation (NASDAQ: TWST) and Western Digital (NASDAQ: WDC) to create and promote an interoperable storage ecosystem based on DNA as a data storage medium, today announced the appointments of CATALOG Technologies and Quantum Corporation to the governing board of the Alliance.

Key Points: 
  • The DNA Data Storage Alliance, a SNIA Technology Affiliate, formed in 2020 by Illumina, Inc. (NASDAQ: ILMN), Microsoft (Nasdaq: MSFT), Twist Bioscience Corporation (NASDAQ: TWST) and Western Digital (NASDAQ: WDC) to create and promote an interoperable storage ecosystem based on DNA as a data storage medium, today announced the appointments of CATALOG Technologies and Quantum Corporation to the governing board of the Alliance.
  • All three new board members bring to the Alliance extensive storage expertise and experience launching new technologies.
  • “SNIA welcomes the expansion of the DNA Data Storage Alliance board with the addition of Quantum and CATALOG.
  • “SNIA and the DNA Data Storage Alliance are already making great strides to make this goal a reality.”
    “DNA data storage is primed to be a game-changer in data storage, providing the ability to efficiently store vast amounts of data for a long time,” said Don Doerner, technical director, Office of the CTO at Quantum Corporation.

Illumina launches new software to enable tertiary analysis for oncology applications, and soon rare disease

Retrieved on: 
Monday, March 27, 2023
SBS, Informatics, DNA, VCF, University, Workflow, Microsoft Office, Abla Mehio Sibai, CGP, Comparison of Direct Connect software, Insight, NGS, Connected, Pathology, Head, Microsoft, RNA, Washington University in St. Louis, Jackson Laboratory, University Hospital Heidelberg, SAN, Illumina, Inc., Cancer, WGS, Diagnosis, Office, WES, Health, Software, Medical imaging, Computer data storage, Medical device, Illumina

SAN DIEGO, March 27, 2023 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced the release of Connected Insights, a new cloud-based software enabling tertiary analysis for clinical next-generation sequencing (NGS) data.

Key Points: 
  • The initial release will support somatic oncology applications, coinciding with the increasing use of comprehensive genomic profiling (CGP) for advanced tumors.
  • Ultimately it is designed to support a diverse range of applications, soon including whole-genome sequencing (WGS) for rare disease.
  • Connected Insights is assay-agnostic and compatible with variant calling files (VCF) from any secondary analysis solution, including Illumina's DRAGEN secondary analysis.
  • As the use of clinical NGS testing grows, Illumina will expand the software's capabilities across other disease areas.

Illumina Issues Statement in Response to Carl Icahn's Letter

Retrieved on: 
Friday, March 24, 2023
Insurance, DNA, D&O, Suggestion, Disclosure, Risk management, GRAIL, Acquisition, Financial Times, SAN, Letter, Real-time, Illumina, Inc., D, Financial adviser, Illumina

All major U.S. public companies, including Illumina, regularly review their D&O insurance to reflect appropriate coverage.

Key Points: 
  • All major U.S. public companies, including Illumina, regularly review their D&O insurance to reflect appropriate coverage.
  • As the Financial Times reported earlier today, "it is not uncommon for a company buying another business to increase insurance limits during the acquisition process."
  • To keep investors informed, Illumina regularly shares relevant corporate risk factors, including those related to GRAIL.
  • Mr. Icahn has no ability to accelerate the legal and regulatory processes and neither do his nominees.

Genetic Testing Market to Reach $28.24 Billion by 2030 - Market Size, Share, Forecasts, & Trends Analysis Report by Meticulous Research®

Retrieved on: 
Monday, March 20, 2023
Glaucoma, DNA, Ventricular septal defect, Prevalence, Impact, Viral Research and Diagnostic Laboratories, Parent, Hospital, Pharmacogenomics, COVID-19, Cancer, Down syndrome, Genetic testing, Diagnosis, Genomics, Hemoglobinopathy, Disorder, Government, PerkinElmer, Fragile X syndrome, MUFG Americas Holdings Corporation, Thermo Fisher Scientific, Patient, Laboratory, Risk, Developed country, Preimplantation genetic diagnosis, Investment, Labcorp, Consumables, Cystic fibrosis, Carrier, Hospital Clinic Manuel Quintela, Association for Molecular Pathology v. Myriad Genetics, Inc., Rare, Illumina, Inc., Geography, Pharmaceutical industry, Dietary supplement, Chromosome, Prenatal development

Genetic testing is done to look at changes in the DNA, sometimes called variants or mutations, that can lead to chronic diseases.

Key Points: 
  • Genetic testing is done to look at changes in the DNA, sometimes called variants or mutations, that can lead to chronic diseases.
  • Genetic testing is performed for different reasons, including pre-symptomatic and predictive testing, pharmacogenetics, diagnostic testing, carrier testing, prenatal testing, preimplantation testing, and newborn screening.
  • Genetic testing has applications in different areas of healthcare and has various advantages, such as determining the likelihood of parents passing the genetic mutation to their offspring.
  • Quick Buy – Genetic Testing Market Research Report: https://www.meticulousresearch.com/Checkout/33822956
    Based on end user, in 2023, the hospitals & clinics segment is expected to account for the largest share of this market.